Related Experiment Video
Updated: Mar 27, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Lack of association between GSTP1 Ile105Val polymorphism and coronary heart disease risk: a meta-analysis
1Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital Zhengzhou 450003, China.
Abstract:
Many epidemiological studies have evaluated the association between GSTP1 Ile105Val polymorphism and coronary heart disease risk, but the results were inconsistent. This study aims re-evaluate the association between GSTP1 Ile105Val Polymorphism and coronary heart disease risk with a meta-analysis. We performed a search in the PubMed, Springer and Elsevier and ran a meta-analysis based on 8 case-control studies that included 3,888 cases and 3,476 controls. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. The results showed that there was no significant association between GSTP1 Ile105Val Polymorphism and coronary heart disease risk susceptibility in the overall population (GG vs. AA: OR = 0.98, 95% CI = 0.84-1.15; GA vs. AA: OR = 1.04, 95% CI = 0.84-1.29; GA/GG vs. AA: OR = 1.02, 95% CI = 0.84-1.25; GG vs.
Aa/Ga:
OR = 0.94, 95% CI = 0.81-1.09). Subgroup analysis stratified by ethnicity and source of control showed no significant association with any genetic model. Our meta-analysis showed that GSTP1 Ile105Val polymorphisms might not be significantly associated with coronary heart disease risk.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets
Single Nucleotide Polymorphisms-SNPs

